Functional Diagnostics in Missouri

Cardiovascular Imaging Technologies, LLC (CVIT) develops and distributes advanced cardiac imaging software solutions for PET and SPECT myocardial perfusion analysis. The company's flagship product, ImagenQ 3.0, is a quantitative myocardial blood flow analysis platform designed for rapid, automated processing of cardiac PET imaging data. ImagenQ 3.0 delivers end-to-end analysis in under 60 seconds with robust quality control tools including ROI assessment, splenic shut-off detection, and arterial input function curve analysis. The software supports multiple PET tracers (Rb-82, N-13 ammonia, F-18 flurpiridaz) and is compatible with most PET/CT systems and image review platforms. CVIT also supplies the Cedars Cardiac Suite, an established standard for PET and SPECT myocardial perfusion imaging. The company provides comprehensive technical support, clinical training, and research laboratory services to support clinical trial endpoints and advance nuclear cardiology imaging. CVIT maintains an in-house imaging core lab staffed by internationally recognized nuclear medicine professionals and operates a real-time support model emphasizing direct clinician access to technical expertise. The company serves hospital nuclear medicine departments, cardiovascular centers, and research institutions performing cardiac imaging and myocardial perfusion studies.

iRT Systems GmbH manufactures the Integral Quality Monitor (IQM) System, a real-time verification device for radiation therapy treatment delivery. The IQM System represents a paradigm shift in radiation therapy quality assurance by providing fully automated, real-time verification of complex treatment techniques without user intervention. The device integrates seamlessly into clinical workflows and performs independent verification of beam product quality and treatment plan delivery. IQM is designed to reduce quality assurance time while maintaining or exceeding the error detection capability of conventional 3D phantom-based methods. The system has been clinically evaluated at leading radiation oncology centers worldwide, including Johns Hopkins University, University of California at Davis, Princess Margaret Cancer Centre, and multiple European institutions. The device complies with EU regulatory requirements, including the 2013/59/EURATOM directive on radiation protection. iRT Systems serves radiation oncology departments and cancer centers globally, with reference sites across North America and Europe. The company actively participates in major oncology conferences including ESTRO, AAPM, DEGRO, and ICON, demonstrating commitment to clinical education and advancement of radiation therapy quality standards.

Curium is the world's leading radiopharmaceutical manufacturer and provider, delivering nuclear medicine solutions across diagnostic imaging and therapeutic applications. The company manufactures and distributes radiopharmaceuticals (SPECT and PET agents) used in oncology, cardiology, and neurology imaging. Curium operates a global network of 4 manufacturing facilities, 1 molybdenum-99 processing plant, 45+ radiopharmacies, and 6,000+ customer locations across 70+ countries, serving approximately 15 million patients annually. The company maintains 100+ years of combined industry heritage and operates multiple regional headquarters and manufacturing centers including facilities in Maryland Heights (MO) and Noblesville (IN) in the United States, as well as production sites in Finland, the Netherlands, France, and Austria. Curium's portfolio includes 50+ radiopharmaceutical products for PET and SPECT imaging. The organization employs 5,000+ skilled professionals and maintains a commitment to quality, innovation, and service reliability. Regulatory compliance and manufacturing standards align with international requirements for pharmaceutical and medical device production in nuclear medicine.

MediBeacon Inc. is a medical technology company specializing in fluorescent tracer agents and transdermal detection technology for non-invasive physiological monitoring. The company's proprietary platform enables real-time measurement and monitoring of vital organ function through biocompatible fluorescent agents that are sensed through the skin via transdermal optical sensors. Primary clinical focus areas include nephrology (kidney function assessment via transdermal GFR measurement), gastroenterology (gut barrier permeability assessment), ophthalmology (fluorescent angiography for retinal vasculature visualization), and surgical applications (intraoperative visualization and identification of anatomical structures). MediBeacon's Transdermal GFR (TGFR) System received FDA PMA approval (P230019) and CE Mark for human clinical use. The company serves leading academic medical centers, research institutes, contract research organizations (CROs), and pharmaceutical companies globally for both preclinical research and clinical applications. MediBeacon maintains offices in St. Louis, Missouri (USA), Mannheim, Germany, and partnerships in Greater China through Huadong Medicine Co., Ltd.